ClinicalTrials.gg
CompletedNCT03306264Updated Aug 27, 2024Results posted

Study of ASTX727 vs IV Decitabine in Participants With MDS, CMML, and AML

A Phase 3 interventional study of ASTX727 and Dacogen in Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia and Acute Myeloid Leukemia, sponsored by Astex Pharmaceuticals, Inc.. Completed at 84 sites in 10 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-08-27.

Sponsored by Astex Pharmaceuticals, Inc. (part of Otsuka Holdings Co., Ltd.) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
227
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 17 studies in Myelodysplastic Syndromes by Otsuka Holdings Co., Ltd. — 5 open to participants now, 7 under way, 2 of them phase 3. Myelodysplastic Syndromes · Otsuka Holdings Co., Ltd..

Enrollment
4th of 16
227 · median 70
Started
2018
with 2 others
Phase 3
4 of 17
none open now
Registered
5th of 17
by date

Among the 17 studies in Myelodysplastic Syndromes by Otsuka Holdings Co., Ltd., this one is the 4th largest by enrollment of the 16 interventional ones that give a count, is one of 3 that started in 2018, is one of 4 in phase 3, and was the 5th registered.

Myelodysplastic Syndromes

1,997 studies on the registry are indexed under Myelodysplastic Syndromes; 323 are open to participants now.

Browse Myelodysplastic Syndromes studies →

Open to participants now

5 of the 17 studies in Myelodysplastic Syndromes by Otsuka Holdings Co., Ltd. are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Who these studies take

Of the 264 Myelodysplastic Syndromes studies recruiting now, 167 (63%) set no upper age limit and 70 (27%) stop at 75 or younger; 57 take children under 18; 17 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies in Myelodysplastic Syndromes by Otsuka Holdings Co., Ltd., or all of them as a file.
02

Study summary

Multicenter PK study of ASTX727 versus IV decitabine. Adult participants who were candidates to receive IV decitabine were randomized 1:1 to receive the ASTX727 tablet Daily×5 in Cycle 1 followed by IV decitabine 20 mg/m\^2 Daily×5 in Cycle 2, or the converse order. After completion of PK studies during the first 2 treatment cycles, participants continued to receive treatment with ASTX727 from Cycle 3 onward (in 28-day cycles) until disease progression, unacceptable toxicity, or the participants discontinued treatment or withdrew from the study.

Read the detailed description

This Phase 3 study established PK equivalence of ASTX727 to IV decitabine in approximately 227 evaluable participants. Eligible participants were randomized to receive both study treatments: oral investigational drug ASTX727, and IV decitabine, as follows: participants were randomly assigned 1:1 to receive ASTX727 or IV decitabine in Cycle 1 and then cross over to the other therapy in Cycle 2.

In the ASTX727 cycle, participants received the ASTX727 tablet Daily×5. Serial PK measurements (blood draws) were done on Days 1, 2, and 5, along with pre-dose PK assessments on Days 1-5 and an assessment at 3 hours post-dose on Day 3. Participants were required to fast from food for 4 hours on days when receiving ASTX727: at least 2 hours before and 2 hours after dosing.

In the IV decitabine cycle, participants received a 1-hour infusion of IV decitabine 20 mg/m\^2 Daily×5. Serial PK measurements were done on Days 1 and 5, along with pre-dose and 1-hour post-infusion assessments on Day 3.

In Cycles ≥3, participants received the ASTX727 tablet Daily×5 in 28-day cycles. (No PK assessments were done from Cycle 3 onward.)

03

Conditions studied

  • Myelodysplastic Syndromes
  • Chronic Myelomonocytic Leukemia
  • Acute Myeloid Leukemia

Keywords

  • MDS
  • CMML
  • decitabine
  • Myelodysplastic Syndromes
  • Chronic Myelomonocytic Leukemia
  • Acute Myeloid Leukemia
  • AML
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Able to understand and comply with the study procedures, understand the risks involved in the study, and provide written before the first study-specific procedure; specifically able to comply with the PK assessment schedule during the first 2 treatment cycles.
  2. Men or women ≥18 years who are candidates to receive IV decitabine according to FDA or European Medicines Agency (EMA) approved indications:

    1. In North America: Participants with MDS previously treated or untreated with de novo or secondary MDS, including all French-American-British subtypes ( anemia, refractory anemia with ringed sideroblasts, refractory anemia with excess blasts, refractory anemia with excess blasts in transformation, and chronic myelomonocytic leukemia [CMML]), and subjects with MDS International Prognostic Scoring System (IPSS) int-1, -2, or high-risk MDS.
    2. In Europe: Participants with de novo or secondary AML, as defined by the World Health Organization (WHO) criteria, who are not candidates for standard induction chemotherapy.
  3. (ECOG) performance status of 0 to 1.
  4. Adequate organ function defined as follows:

    1. Hepatic: Total or direct ≤2 × (ULN); /serum glutamic oxaloacetic transaminase (AST/SGOT) and alanine transaminase/serum glutamic pyruvic transaminase (ALT/SGPT) ≤2.5 × ULN.
    2. Renal: serum creatinine ≤1.5 × ULN or calculated or >50 mL/min/1.73 m2 for subjects with creatinine levels above institutional normal.
  5. No major surgery within 30 days of first study treatment.
  6. of at least 3 months.
  7. Women of must not be pregnant or breastfeeding and must have a negative pregnancy test at screening. Women of non-childbearing potential are those who have had a hysterectomy or bilateral oophorectomy, or who have completed menopause, defined as no menses for at least 1 year AND either age ≥65 years or follicle-stimulating hormone levels in the menopausal range.
  8. Subjects and their partners with must agree to use effective measures during the study and for 3 months after the last dose of study treatment. Effective contraception includes methods such as oral contraceptives or double-barrier method (eg, use of a condom AND diaphragm, with spermicide).

Exclusion criteria

Exclusion Criteria:

  1. Prior treatment with more than 1 cycle of azacitidine or decitabine. Prior cytotoxic chemotherapy for AML except for hydroxyurea to control high white blood cell (WBC) counts.
  2. Hospitalization for more than 2 days for documented febrile neutropenia, pneumonia, sepsis, or systemic infection in the 30 days before screening.
  3. Treatment with any drug or therapy within 2 weeks of study treatment, or 5 half-lives, whichever is longer, before the first dose of study treatment, or ongoing adverse events (AEs) from previous treatment.
  4. Cytotoxic chemotherapy or prior azacitidine or decitabine within 4 weeks of first dose of study treatment.
  5. Concurrent MDS therapies, including lenalidomide, erythropoietin, cyclosporine/tacrolimus, granulocyte-colony stimulating factor (G-CSF), granulocyte-macrophage colony-stimulating factor, etc. (Prior treatment with these agents is permitted, provided that completion is at least 1 week before the first dose of study treatment.)
  6. Poor medical risk because of other conditions such as uncontrolled systemic diseases, active uncontrolled infections, or comorbidities that may put the patient at risk of not being able to complete at least 2 cycles of treatment.
  7. Known significant mental illness or other condition, such as active alcohol or other substance abuse or addiction, that in the opinion of the investigator predisposes the subject to high risk of noncompliance with the protocol.
  8. Rapidly progressive or highly proliferative disease (total white blood cell count of >15 × 10\^9/L) or other criteria that render the subject at high risk of requiring intensive cytotoxic chemotherapy within the next 3 months.
  9. Life-threatening illness or severe organ system dysfunction, such as uncontrolled congestive heart failure or , or other reasons including laboratory abnormalities, which, in the investigator's opinion, could compromise the subject's safety, interfere with the absorption or metabolism of ASTX727, or compromise completion of the study or integrity of the study outcomes.
  10. Prior , except for adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, prostate cancer or breast cancer under control with hormone therapy, or other cancer from which the subject has been disease free for at least 2 years.
Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
227 participants (actual)

Study arms

  • Experimental
    MDS or CMML: Sequence A: First ASTX727, Then IV Decitabine, Then ASTX727

    Participants with MDS or CMML received ASTX727 tablet, containing the fixed-dose combination of 35 mg decitabine and 100 mg cedazuridine, orally, once daily, on Days 1 to 5 in cycle 1 (each cycle = 28 days), followed by IV infusion of decitabine 20 mg/m\^2, once daily, on Days 1 to 5 in cycle 2. A washout period of 23 days was maintained between the 2 cycles. From cycle 3, all participants enrolled in cycles 1 and 2 received ASTX727 tablet, once daily, on Days 1 to 5 of each 28-day cycle until disease progression, unacceptable toxicity, treatment discontinuation for other reasons, or withdrawal from the study.

    Drug: ASTX727 · Drug: Dacogen

  • Experimental
    MDS or CMML: Sequence B: First IV Decitabine, Then ASTX727, Then ASTX727

    Participants with MDS or CMML received IV infusion of decitabine 20 mg/m\^2, once daily, on Days 1 to 5 in cycle 1 (each cycle = 28 days) followed by ASTX727 tablet, containing the fixed-dose combination of 35 mg decitabine and 100 mg cedazuridine, orally, once daily, on Days 1 to 5 in cycle 2. A washout period of 23 days was maintained between the 2 cycles. From cycle 3, all participants enrolled in cycles 1 and 2 received ASTX727 tablet, once daily, on Days 1 to 5 of each 28-day cycle until disease progression, unacceptable toxicity, treatment discontinuation for other reasons, or withdrawal from the study.

    Drug: ASTX727 · Drug: Dacogen

  • Experimental
    AML: Sequence A: First ASTX727, Then IV Decitabine, Then ASTX727

    Participants with AML received ASTX727 tablet, containing the fixed-dose combination of 35 mg decitabine and 100 mg cedazuridine, orally, once daily, on Days 1 to 5 in cycle 1 (each cycle = 28 days), followed by IV infusion of decitabine 20 mg/m\^2, once daily, on Days 1 to 5 in cycle 2. A washout period of 23 days was maintained between the 2 cycles. From cycle 3, all participants enrolled in cycles 1 and 2 received ASTX727 tablet, once daily, on Days 1 to 5 of each 28-day cycle until disease progression, unacceptable toxicity, participant discontinued treatment, or was withdrawn from the study.

    Drug: ASTX727 · Drug: Dacogen

  • Experimental
    AML: Sequence B: First IV Decitabine, Then ASTX727, Then ASTX727

    Participants with AML received IV infusion of decitabine 20 mg/m\^2, once daily, on Days 1 to 5 in cycle 1 (each cycle = 28 days) followed by ASTX727 tablet, containing the fixed-dose combination of 35 mg decitabine and 100 mg cedazuridine, orally, once daily, on Days 1 to 5 in cycle 2. A washout period of 23 days was maintained between the 2 cycles. From cycle 3, all participants enrolled in cycles 1 and 2 received ASTX727 tablet, once daily, on Days 1 to 5 of each 28-day cycle until disease progression, unacceptable toxicity, participant discontinued treatment, or was withdrawn from the study.

    Drug: ASTX727 · Drug: Dacogen

Interventions

  • DrugASTX727

    ASTX727 oral tablet

    Also known as: decitabine 35 mg + cedazuridine 100 mg

  • Decitabine 20 mg/m\^2 one-hour IV infusion

    Also known as: decitabine

06

What researchers measure

Primary outcomes

  1. Total 5-day Area Under the Curve From 0 to 24 Hours (AUC0-24) After Treatment With ASTX727 And IV Decitabine

    Total 5-day ASTX727 AUC0-24 exposures were calculated using PK data from 3 days of serial PK sampling, Day 1 AUC0-24 (first ASTX727 dose) was added to (Day 2 AUC0-24+ Day 5 AUC0-24) × 2. Decitabine 5-day AUC0-24 exposures after IV decitabine were calculated as follows: (Day 1 AUC0-24+ Day 5 AUC0-24) / 2 was multiplied by 5. If AUC0-24 on Day 2 (for ASTX727) or Day 1 (IV decitabine) was not available, it was replaced by AUC0-24 on Day 5; the converse was also true.

    Time frame: ASTX727: Pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 24 hours post-dose on Days 1 to 5 of Cycle 1 and 2; Decitabine: Pre-dose, 0.25, 0.5, 1, 1.08, 1.5, 2, 3, 4, 6, 8 hours post-dose on Days 1 to 5 of Cycle 1 and 2 (each cycle= 28 days)

Secondary outcomes

  1. MDS/CMML: Number of Participants With Treatment-emergent Adverse Events (TEAEs)

    An AE is defined as any untoward medical occurrence in a clinical investigation participants administered a drug; it does not necessarily have to have a causal relationship with this treatment. TEAEs were defined as events that first occurred or worsened on or after the date of the first dose of study treatment until 30 days after the last dose of study treatment or until the start of a post-treatment alternative anti-cancer treatment, whichever occurred first.

    Time frame: From randomization up to 30 days after last dose of study treatment (up to approximately 2.7 years)

  2. AML: Number of Participants With Treatment-emergent Adverse Events (AEs)

    An AE is defined as any untoward medical occurrence in a clinical investigation participants administered a drug; it does not necessarily have to have a causal relationship with this treatment. TEAEs were defined as events that first occurred or worsened on or after the date of the first dose of study treatment until 30 days after the last dose of study treatment or until the start of a post-treatment alternative anti-cancer treatment, whichever occurred first.

    Time frame: From randomization up to 30 days after last dose of study treatment (up to approximately 2.4 years)

  3. MDS/CMML: Number of Participants With Grade 3 or Higher TEAEs

    TEAEs were defined as events that first occurred or worsened on or after the date of the first dose of study treatment until 30 days after the last dose of study treatment or until the start of a post-treatment alternative anti-cancer treatment, whichever occurred first. Severity of AEs were graded using Common Terminology Criteria for Adverse Events (CTCAE) version 4.03. Grade 1: Mild; Grade 2: Moderate; Grade 3: Severe; Grade 4: Life-threatening; Grade 5: Fatal.

    Time frame: From randomization up to 30 days after last dose of study treatment (up to approximately 2.7 years)

  4. AML: Number of Participants With Grade 3 or Higher TEAEs

    TEAEs were defined as events that first occurred or worsened on or after the date of the first dose of study treatment until 30 days after the last dose of study treatment or until the start of a post-treatment alternative anti-cancer treatment, whichever occurred first. Severity of AEs were graded using CTCAE version 4.03. Grade 1: Mild; Grade 2: Moderate; Grade 3: Severe; Grade 4: Life-threatening; Grade 5: Fatal.

    Time frame: From randomization up to 30 days after last dose of study treatment (up to approximately 2.4 years)

  5. Maximum Percentage of Long Interspersed Nucleotide Elements (LINE)-1 Demethylation

    Summarized data for Cycle 1 and Cycle 2 was reported.

    Time frame: Pre-dose on Day 1 of Cycles 1 and 2 (as Baseline), and Days 8, 15 and 22 of Cycles 1 and 2 (each cycle= 28 days)

  6. Total 5-day Area Under the Curve From 0 to Infinity (AUC0-inf) After Treatment With ASTX727 And IV Decitabine

    Total 5-day ASTX727 AUC0-inf exposures were calculated using PK data from 3 days of serial PK sampling, Day 1 AUC0-inf (first ASTX727 dose) was added to (Day 2 AUC0-inf+ Day 5 AUC0-inf) × 2. Decitabine 5-day AUC0-inf exposures after IV decitabine were calculated as follows: (Day 1 AUC0-inf+ Day 5 AUC0-inf) / 2 was multiplied by 5. If AUC0-inf on Day 2 (for ASTX727) or Day 1 (IV decitabine) was not available, it was replaced by AUC0-inf on Day 5; the converse was also true.

    Time frame: ASTX727: Pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 24 hours post-dose on Days 1 to 5 of Cycle 1 and 2; Decitabine: Pre-dose, 0.25, 0.5, 1, 1.08, 1.5, 2, 3, 4, 6, 8 hours post-dose on Days 1 to 5 of Cycle 1 and 2 (each cycle= 28 days)

  7. Total 5-day Area Under the Curve From 0 to Last Quantifiable Concentration (AUC0-last) After Treatment With ASTX727 And IV Decitabine

    Total 5-day ASTX727 AUC0-last exposures were calculated using PK data from 3 days of serial PK sampling, Day 1 AUC0-last (first ASTX727 dose) was added to (Day 2 AUC0-last + Day 5 AUC0-last) × 2. Decitabine 5-day AUC0-last exposures after IV decitabine were calculated as follows: (Day 1 AUC0-last + Day 5 AUC0-last) / 2 was multiplied by 5. If AUC0-last on Day 2 (for ASTX727) or Day 1 (IV decitabine) was not available, it was replaced by AUC0-last on Day 5; the converse was also true.

    Time frame: ASTX727: Pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 24 hours post-dose on Days 1 to 5 of Cycle 1 and 2; Decitabine: Pre-dose, 0.25, 0.5, 1, 1.08, 1.5, 2, 3, 4, 6, 8 hours post-dose on Days 1 to 5 of Cycle 1 and 2 (each cycle= 28 days)

  8. Total 5-day Area Under the Curve From 0 to 8 Hours (AUC0-8) After Treatment With ASTX727 And IV Decitabine

    Total 5-day ASTX727 AUC0-8 exposures were calculated using PK data from 3 days of serial PK sampling, Day 1 AUC0-8 (first ASTX727 dose) was added to (Day 2 AUC0-8 + Day 5 AUC0-8) × 2. Decitabine 5-day AUC0-8 exposures after IV decitabine were calculated as follows: (Day 1 AUC0-8 + Day 5 AUC0-8) / 2 was multiplied by 5. If AUC0-8 on Day 2 (for ASTX727) or Day 1 (IV decitabine) was not available, it was replaced by AUC0-8 on Day 5; the converse was also true.

    Time frame: ASTX727: Pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8 hours post-dose on Days 1 to 5 of Cycle 1 and 2; Decitabine: Pre-dose, 0.25, 0.5, 1, 1.08, 1.5, 2, 3, 4, 6, 8 hours post-dose on Days 1 to 5 of Cycle 1 and 2 (each cycle= 28 days)

  9. Area Under the Curve From 0 to Infinity (AUC0-inf) After Treatment With ASTX727 And IV Decitabine

    AUC0-inf was calculated using the formula AUClast + (Clast / λZ), where Clast is the last quantifiable concentration and λZ is the elimination rate constant. AUC0-inf will be calculated using the linear up-log down method. Summarized data has been reported for cycle 1 and 2.

    Time frame: ASTX727: Pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 24 hours post-dose on Days 1, 2 and 5 of Cycle 1 and 2; Decitabine: Pre-dose, 0.25, 0.5, 1, 1.08, 1.5, 2, 3, 4, 6, 8 hours post-dose on Days 1 and 5 of Cycle 1 and 2 (each cycle= 28 days)

  10. Maximum Observed Plasma Concentration (Cmax) of Decitabine, Cedazuridine, and Cedazuridine-epimer

    Summarized data of Cmax on Day 1, 2 and 5 respectively for Cycle 1 and 2 has been reported for ASTX727. Similarly, summarized data of Cmax on Day 1 and 5 respectively for Cycle 1 and 2 has been reported for IV Decitabine.

    Time frame: ASTX727: Pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 24 hours post-dose on Days 1, 2 and 5 of Cycle 1 and 2; Decitabine: Pre-dose, 0.25, 0.5, 1, 1.08, 1.5, 2, 3, 4, 6, 8 hours post-dose on Days 1 and 5 of Cycle 1 and 2 (each cycle= 28 days)

  11. Time to Reach Maximum Plasma Concentration (Tmax) of Decitabine, Cedazuridine, and Cedazuridine-epimer

    Summarized data of Tmax on Day 1, 2 and 5 respectively for Cycle 1 and 2 has been reported for ASTX727. Similarly, summarized data of Tmax on Day 1 and 5 respectively for Cycle 1 and 2 has been reported for IV Decitabine.

    Time frame: ASTX727: Pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 24 hours post-dose on Days 1, 2 and 5 of Cycle 1 and 2; Decitabine: Pre-dose, 0.25, 0.5, 1, 1.08, 1.5, 2, 3, 4, 6, 8 hours post-dose on Days 1 and 5 of Cycle 1 and 2 (each cycle= 28 days)

  12. Apparent Oral Clearance (CL/F) of Oral Decitabine and Cedazuridine

    Oral CL/F for oral decitabine was measured only on Day 1 and oral CL/F for oral cedazuridine was measured on Days 1, 2 and 5. Summarized data of Oral CL/F for oral decitabine on Day 1 for Cycle 1 and 2 has been reported for ASTX727. Similarly, summarized data of oral CL/F for oral cedazuridine on Day 1,2 and 5 respectively for Cycle 1 and 2 has been reported for ASTX727.

    Time frame: Pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 24 hours post-dose on Days 1, 2 and 5 of Cycle 1 and 2 (each cycle= 28 days)

  13. Apparent Elimination Half Life (t1/2) of Decitabine, Cedazuridine, and Cedazuridine-epimer

    Summarized data of t1/2 on Day 1, 2 and 5 respectively for Cycle 1 and 2 has been reported for ASTX727. Similarly, summarized data of t1/2 on Day 1 and 5 respectively for Cycle 1 and 2 has been reported for IV Decitabine.

    Time frame: ASTX727: Pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 24 hours post-dose on Days 1, 2 and 5 of Cycle 1 and 2; Decitabine: Pre-dose, 0.25, 0.5, 1, 1.08, 1.5, 2, 3, 4, 6, 8 hours post-dose on Days 1 and 5 of Cycle 1 and 2 (each cycle= 28 days)

  14. Apparent Volume of Distribution (Vz/F) of Oral Decitabine and Cedazuridine

    Summarized data of Vz/F on Day 1, 2 and 5 respectively for Cycle 1 and 2 has been reported for ASTX727.

    Time frame: Pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 24 hours post-dose on Days 1, 2 and 5 of Cycle 1 and 2 (each cycle= 28 days)

  15. MDS/CMML: Percentage of Participants With Complete Response (CR), Marrow CR (mCR), Partial Response (PR), Hematologic Improvement (HI) Based on International Working Group (IWG) 2006 Myelodysplastic Syndromes (MDS) Response Criteria

    CR: normal peripheral, persistent granulocyte count ≥1.0x10\^9/liter(L), platelet ≥100x10\^9/L, Hemoglobin (Hgb) ≥11g/dL, normal bone marrow with persistent marrow blasts ≤5%. mCR: reduction of bone marrow blasts to≤5%, decrease by 50% or more with/without normalization of peripheral counts.PR: normal peripheral counts, granulocyte count ≥1.0x10\^9/L, platelet count ≥100x10\^9/L, Hgb ≥11 g/dL, normal bone marrow, marrow blasts \>5%, reduced by 50% or more for at least 4 weeks. HI: HI-E: Hb increase ≥1.5 g/dL in absence of RBC transfusions. HI-P: Absolute increase of platelet count from \<20 to \>20X10\^9/L by at least 100%,if more than 20x10\^9/L, by absolute increase of at least 30x10\^9/L in absence of platelet transfusions. HI-N: granulocyte increase ≥100%, by an absolute increase ≥0.5x10\^9/L for at least 8 weeks. Percentage of participants with CR, mCR, PR, and HI based on IWG 2003 MDS response criteria are reported. Response has been reported based on participants with MDS or CMML.

    Time frame: Up to approximately 2.7 years

  16. AML: Percentage of Participants With CR, CR With Incomplete Blood Count Recovery (CRi), CR With Incomplete Platelet Recovery (CRp), and CR Plus CRp Based on IWG 2003 AML Response Criteria

    CR was defined as absolute neutrophil content (ANC) ≥1000/ microliter (μL), platelets ≥100,000/μL, independence from red blood cell (RBC) and platelet transfusions over the past week, no leukemic blasts and \<5% leukemic blasts. CRp was defined as CR criteria except platelets \<100,000/μL.and platelet transfusion over the past week. CRi was defined as CR criteria except ANC \<1000/μL or platelets \<100,000/μL. Percentage of participants with CR, CRi, CRp, and CR Plus CRp based on IWG 2003 AML response criteria are reported.

    Time frame: Up to approximately 2.4 years

  17. AML: Percentage of Participants With CR With Partial Hematologic Recovery (CRh) Based on IWG 2003 AML Response Criteria

    CRh was defined as \<5% of blasts in the bone marrow, no evidence of disease, and partial recovery of peripheral blood counts (platelets \>50,000/μL and ANC \>500/μL), independence from RBC and platelet transfusions within 7 days of bone marrow evaluation, and peripheral blast ≤1%. Percentage of participants with CRh based on IWG 2003 AML response criteria are reported.

    Time frame: Day 1 of Cycle 3 up to approximately 2.4 years (each cycle= 28 days)

  18. AML: Time to First Response, Best Response and Complete Response Based on IWG 2003 AML Response Criteria

    Time to first response was defined as time in months from the date of first treatment to the first date when any response is achieved. Time to best response was defined in months from the date of first treatment to the first date when a subject's best response, in the order of CR, CRi (or CRp or CRh), or PR, was achieved. Time to CR was defined in months from the date of first treatment to the first date when CR is achieved. CR:ANC ≥1000/ microliter (μL),platelets ≥100,000/μL,independence from RBC and platelet transfusions over the past week, no leukemic blasts, and \<5% leukemic blasts.CRp: CR criteria except ANC ≥1000/μL, platelets \< 100,000/μL.and platelet transfusion over the past week. CRi:CR criteria except ANC \<1000/μL or platelets \<100,000/μL.CRh: \<5% of blasts in the bone marrow,platelets \>50,000/μL and ANC \>500/μL, independence from RBC and platelet transfusions within 7 days and peripheral blast ≤1%. PR: CR criteria except decrease of ≥50% in leukemic blasts.

    Time frame: Up to approximately 2.4 years

  19. AML: Duration of Complete Response and Combined CR and CRh Based on IWG 2003 AML Response Criteria

    Duration of CR was defined as the time interval from the first CR to time of relapse. Duration of combined CR and CRh was defined as the time interval from the first CR or CRh to time of relapse. Duration of CR and combined CR and CRh was presented using a Kaplan-Meier estimate.

    Time frame: Up to approximately 2.4 years

  20. MDS/CMML: Percentage of Participants With Red Blood Cell (RBC) and Platelet Transfusion Independence (TI)

    Transfusion independence was defined as no transfusion for 56 consecutive days or more (84 and 112 days) after the first dose of study treatment while maintaining hemoglobin ≥8 grams/deciliter (g/dL) (RBC TI) or maintaining platelets ≥20×109/L (platelet TI).

    Time frame: Up to approximately 2.7 years

  21. AML: Percentage of Participants With Red Blood Cell (RBC) and Platelet Transfusion Independence (TI)

    Transfusion independence was defined as no transfusion for 56 consecutive days or more (112 days) after the first dose of study treatment while maintaining hemoglobin ≥8 grams/deciliter (g/dL) (RBC TI) or maintaining platelets ≥20×109/L (platelet TI).

    Time frame: Up to approximately 2.4 years

  22. MDS/CMML: Leukemia-free Survival (LFS)

    LFS was defined as time from the date of randomization to the date when bone marrow or peripheral blood blasts reach ≥20%, or death from any cause. Participants who hadn't reached AML at the time of the analysis were censored at the date of the last follow-up. Leukemia-free survival was presented using a Kaplan-Meier estimate.

    Time frame: From randomization up to approximately 2.7 years

  23. MDS/CMML: Overall Survival (OS)

    OS was defined as time from the date of randomization to the date of death from any cause. Participants without documented death at the time of the analysis were censored at the date of the last follow-up. Overall survival was presented using a Kaplan-Meier estimate.

    Time frame: From randomization up to approximately 2.7 years

  24. AML: Overall Survival (OS)

    OS was defined as time from the date of randomization to the date of death from any cause. Participants without documented death at the time of the analysis were censored at the date of the last follow-up. Overall survival was presented using a Kaplan-Meier estimate.

    Time frame: From randomization up to approximately 2.4 years

  25. AML: Survival Rates at 6 Months, 1 Year, and 2 Years

    One-year survival rate was defined as the survival rate at the end of the first year from the date of randomization. The survival rates at 6 months and at 2 years were calculated similarly.

    Time frame: At Month 6, Year 1 and 2

  26. AML: Event-free Survival (EFS)

    EFS was defined as time from the date of randomization to the date of treatment failure \[disease progression/relapse (due to confirmed reappearance of leukemic blasts in peripheral blood or ≥5% leukemic blasts in bone marrow (including relapse), discontinue treatment due to disease progression or treatment-related AE, or alternative anti-leukemia therapy except for HCT\] or death from any cause, whichever occurs first. Participants without documented treatment failure at the time of the analysis were censored at the date of the last follow-up. Event-free survival was presented using a Kaplan-Meier estimate.

    Time frame: From randomization up to approximately 2.4 years

  27. AML: Progression-free Survival (PFS)

    PFS was defined as time from the date of randomization to the date disease progression due to confirmed reappearance of leukemic blasts in peripheral blood or ≥5% leukemic blasts in bone marrow (including relapse) or death from any cause, whichever occurs first. Participants without documented disease progression/relapse or death at the time of the analysis were censored at the date of the last follow-up. Progression-free survival was presented using a Kaplan-Meier estimate.

    Time frame: From randomization up to approximately 2.4 years

07

Results

Posted Jul 1, 2024

Participant flow

A total of 227 participants took part in the study from 15 February 2018 to 25 May 2023. 138 participants with a diagnosis of myelodysplastic syndromes (MDS) or chronic myelomonocytic leukemia (CMML) took part from the United States and Canada. 89 participants with a diagnosis of acute myeloid leukemia (AML) took part from Austria, Canada, Czech Republic, France, Germany, Hungary, Italy, Spain, and United Kingdom.

Participant flow — Overall Study
MilestoneMDS or CMML: Sequence A: First ASTX727, Then IV Decitabine, Then ASTX727MDS or CMML: Sequence B: First IV Decitabine, Then ASTX727, Then ASTX727AML: Sequence A: First ASTX727, Then IV Decitabine, Then ASTX727AML: Sequence B: First IV Decitabine, Then ASTX727, Then ASTX727
Started69694445
Safety analysis set66674344
Completed0000
Not completed69694445
Withdrew: Death33253434
Withdrew: Complete consent withdrawal4418
Withdrew: Lost to follow-up1010
Withdrew: Rollover to astx727-06101842
Withdrew: Study centre terminated by sponsor212241

Outcome measures

PrimaryTotal 5-day Area Under the Curve From 0 to 24 Hours (AUC0-24) After Treatment With ASTX727 And IV Decitabine

Total 5-day ASTX727 AUC0-24 exposures were calculated using PK data from 3 days of serial PK sampling, Day 1 AUC0-24 (first ASTX727 dose) was added to (Day 2 AUC0-24+ Day 5 AUC0-24) × 2. Decitabine 5-day AUC0-24 exposures after IV decitabine were calculated as follows: (Day 1 AUC0-24+ Day 5 AUC0-24) / 2 was multiplied by 5. If AUC0-24 on Day 2 (for ASTX727) or Day 1 (IV decitabine) was not available, it was replaced by AUC0-24 on Day 5; the converse was also true.

Time frame:
ASTX727: Pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 24 hours post-dose on Days 1 to 5 of Cycle 1 and 2; Decitabine: Pre-dose, 0.25, 0.5, 1, 1.08, 1.5, 2, 3, 4, 6, 8 hours post-dose on Days 1 to 5 of Cycle 1 and 2 (each cycle= 28 days)
Reported as:
Geometric mean · hours*nanograms per milliliter (h*ng/mL)
Total 5-day Area Under the Curve From 0 to 24 Hours (AUC0-24) After Treatment With ASTX727 And IV Decitabine
hours*nanograms per milliliter (h*ng/mL)MDS or CMML: IV DecitabineMDS or CMML: ASTX727AML: IV DecitabineAML: ASTX727
Total 5-day Area Under the Curve From 0 to 24 Hours (AUC0-24) After Treatment With ASTX727 And IV Decitabine864.34 ± 40.0855.96 ± 50.6910.1 ± 52.4900.5 ± 52.0
Statistical analysis
  • MDS or CMML: IV Decitabine vs MDS or CMML: ASTX727 · Ratio of geometric lsm: 98.93 · 90% CI 92.66 to 105.6Analysis was based on ANOVA model with treatment, cycle, and sequence as fixed effects, and participant nested in sequence as a random effect (ratio is Oral/IV).
  • AML: IV Decitabine vs AML: ASTX727 · Ratio of geometric lsm: 99.64 · 90% CI 91.23 to 108.8Analysis was based on ANOVA model with treatment, cycle, and sequence as fixed effects, and participant nested in sequence as a random effect (ratio is Oral/IV).
SecondaryMDS/CMML: Number of Participants With Treatment-emergent Adverse Events (TEAEs)

An AE is defined as any untoward medical occurrence in a clinical investigation participants administered a drug; it does not necessarily have to have a causal relationship with this treatment. TEAEs were defined as events that first occurred or worsened on or after the date of the first dose of study treatment until 30 days after the last dose of study treatment or until the start of a post-treatment alternative anti-cancer treatment, whichever occurred first.

Time frame:
From randomization up to 30 days after last dose of study treatment (up to approximately 2.7 years)
Reported as:
Count of participants · Participants
MDS/CMML: Number of Participants With Treatment-emergent Adverse Events (TEAEs)
ParticipantsMDS or CMML: IV DecitabineMDS or CMML: ASTX727
MDS/CMML: Number of Participants With Treatment-emergent Adverse Events (TEAEs)127130
SecondaryAML: Number of Participants With Treatment-emergent Adverse Events (AEs)

An AE is defined as any untoward medical occurrence in a clinical investigation participants administered a drug; it does not necessarily have to have a causal relationship with this treatment. TEAEs were defined as events that first occurred or worsened on or after the date of the first dose of study treatment until 30 days after the last dose of study treatment or until the start of a post-treatment alternative anti-cancer treatment, whichever occurred first.

Time frame:
From randomization up to 30 days after last dose of study treatment (up to approximately 2.4 years)
Reported as:
Count of participants · Participants
AML: Number of Participants With Treatment-emergent Adverse Events (AEs)
ParticipantsAML: IV DecitabineAML: ASTX727
AML: Number of Participants With Treatment-emergent Adverse Events (AEs)7180
SecondaryMDS/CMML: Number of Participants With Grade 3 or Higher TEAEs

TEAEs were defined as events that first occurred or worsened on or after the date of the first dose of study treatment until 30 days after the last dose of study treatment or until the start of a post-treatment alternative anti-cancer treatment, whichever occurred first. Severity of AEs were graded using Common Terminology Criteria for Adverse Events (CTCAE) version 4.03. Grade 1: Mild; Grade 2: Moderate; Grade 3: Severe; Grade 4: Life-threatening; Grade 5: Fatal.

Time frame:
From randomization up to 30 days after last dose of study treatment (up to approximately 2.7 years)
Reported as:
Count of participants · Participants
MDS/CMML: Number of Participants With Grade 3 or Higher TEAEs
ParticipantsMDS or CMML: IV DecitabineMDS or CMML: ASTX727
MDS/CMML: Number of Participants With Grade 3 or Higher TEAEs89121
SecondaryAML: Number of Participants With Grade 3 or Higher TEAEs

TEAEs were defined as events that first occurred or worsened on or after the date of the first dose of study treatment until 30 days after the last dose of study treatment or until the start of a post-treatment alternative anti-cancer treatment, whichever occurred first. Severity of AEs were graded using CTCAE version 4.03. Grade 1: Mild; Grade 2: Moderate; Grade 3: Severe; Grade 4: Life-threatening; Grade 5: Fatal.

Time frame:
From randomization up to 30 days after last dose of study treatment (up to approximately 2.4 years)
Reported as:
Count of participants · Participants
AML: Number of Participants With Grade 3 or Higher TEAEs
ParticipantsAML: IV DecitabineAML: ASTX727
AML: Number of Participants With Grade 3 or Higher TEAEs4373
SecondaryMaximum Percentage of Long Interspersed Nucleotide Elements (LINE)-1 Demethylation

Summarized data for Cycle 1 and Cycle 2 was reported.

Time frame:
Pre-dose on Day 1 of Cycles 1 and 2 (as Baseline), and Days 8, 15 and 22 of Cycles 1 and 2 (each cycle= 28 days)
Reported as:
Least squares mean · percentage of demethylation
Maximum Percentage of Long Interspersed Nucleotide Elements (LINE)-1 Demethylation
percentage of demethylationMDS or CMML: IV DecitabineMDS or CMML: ASTX727AML: IV DecitabineAML: ASTX727
Cycle 114.019 (12.528 to 15.510)13.289 (11.798 to 14.780)8.243 (6.340 to 10.147)9.357 (7.288 to 11.426)
Cycle 211.968 (10.503 to 13.434)11.151 (9.685 to 12.616)8.153 (6.226 to 10.079)8.037 (6.258 to 9.816)
SecondaryTotal 5-day Area Under the Curve From 0 to Infinity (AUC0-inf) After Treatment With ASTX727 And IV Decitabine

Total 5-day ASTX727 AUC0-inf exposures were calculated using PK data from 3 days of serial PK sampling, Day 1 AUC0-inf (first ASTX727 dose) was added to (Day 2 AUC0-inf+ Day 5 AUC0-inf) × 2. Decitabine 5-day AUC0-inf exposures after IV decitabine were calculated as follows: (Day 1 AUC0-inf+ Day 5 AUC0-inf) / 2 was multiplied by 5. If AUC0-inf on Day 2 (for ASTX727) or Day 1 (IV decitabine) was not available, it was replaced by AUC0-inf on Day 5; the converse was also true.

Time frame:
ASTX727: Pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 24 hours post-dose on Days 1 to 5 of Cycle 1 and 2; Decitabine: Pre-dose, 0.25, 0.5, 1, 1.08, 1.5, 2, 3, 4, 6, 8 hours post-dose on Days 1 to 5 of Cycle 1 and 2 (each cycle= 28 days)
Reported as:
Geometric least squares mean · h*ng/mL
Total 5-day Area Under the Curve From 0 to Infinity (AUC0-inf) After Treatment With ASTX727 And IV Decitabine
h*ng/mLMDS or CMML: IV DecitabineMDS or CMML: ASTX727AML: IV DecitabineAML: ASTX727
Total 5-day Area Under the Curve From 0 to Infinity (AUC0-inf) After Treatment With ASTX727 And IV Decitabine866.15 ± 39.9849.63 ± 50.4912.3 ± 52.3902.1 ± 51.8
Statistical analysis
  • MDS or CMML: IV Decitabine vs MDS or CMML: ASTX727 · Ratio of geometric lsm: 98.00 · 90% CI 91.80 to 104.6Analysis was based on ANOVA model with treatment, cycle, and sequence as fixed effects, and participant nested in sequence as a random effect (ratio is Oral/IV).
  • AML: IV Decitabine vs AML: ASTX727 · Ratio of geometric lsm: 99.61 · 90% CI 91.20 to 108.8Analysis was based on ANOVA model with treatment, cycle, and sequence as fixed effects, and participant nested in sequence as a random effect (ratio is Oral/IV).
SecondaryTotal 5-day Area Under the Curve From 0 to Last Quantifiable Concentration (AUC0-last) After Treatment With ASTX727 And IV Decitabine

Total 5-day ASTX727 AUC0-last exposures were calculated using PK data from 3 days of serial PK sampling, Day 1 AUC0-last (first ASTX727 dose) was added to (Day 2 AUC0-last + Day 5 AUC0-last) × 2. Decitabine 5-day AUC0-last exposures after IV decitabine were calculated as follows: (Day 1 AUC0-last + Day 5 AUC0-last) / 2 was multiplied by 5. If AUC0-last on Day 2 (for ASTX727) or Day 1 (IV decitabine) was not available, it was replaced by AUC0-last on Day 5; the converse was also true.

Time frame:
ASTX727: Pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 24 hours post-dose on Days 1 to 5 of Cycle 1 and 2; Decitabine: Pre-dose, 0.25, 0.5, 1, 1.08, 1.5, 2, 3, 4, 6, 8 hours post-dose on Days 1 to 5 of Cycle 1 and 2 (each cycle= 28 days)
Reported as:
Geometric mean · h*ng/mL
Total 5-day Area Under the Curve From 0 to Last Quantifiable Concentration (AUC0-last) After Treatment With ASTX727 And IV Decitabine
h*ng/mLMDS or CMML: IV DecitabineMDS or CMML: ASTX727AML: IV DecitabineAML: ASTX727
Total 5-day Area Under the Curve From 0 to Last Quantifiable Concentration (AUC0-last) After Treatment With ASTX727 And IV Decitabine853.02 ± 40.7837.38 ± 50.7902.7 ± 53.0881.8 ± 52.5
Statistical analysis
  • MDS or CMML: IV Decitabine vs MDS or CMML: ASTX727 · Ratio of geometric lsm: 98.11 · 90% CI 91.88 to 104.8Analysis was based on ANOVA model with treatment, cycle, and sequence as fixed effects, and participant nested in sequence as a random effect (ratio is Oral/IV).
  • AML: IV Decitabine vs AML: ASTX727 · Ratio of geometric lsm: 98.11 · 90% CI 89.75 to 107.2Analysis was based on ANOVA model with treatment, cycle, and sequence as fixed effects, and participant nested in sequence as a random effect (ratio is Oral/IV).
SecondaryTotal 5-day Area Under the Curve From 0 to 8 Hours (AUC0-8) After Treatment With ASTX727 And IV Decitabine

Total 5-day ASTX727 AUC0-8 exposures were calculated using PK data from 3 days of serial PK sampling, Day 1 AUC0-8 (first ASTX727 dose) was added to (Day 2 AUC0-8 + Day 5 AUC0-8) × 2. Decitabine 5-day AUC0-8 exposures after IV decitabine were calculated as follows: (Day 1 AUC0-8 + Day 5 AUC0-8) / 2 was multiplied by 5. If AUC0-8 on Day 2 (for ASTX727) or Day 1 (IV decitabine) was not available, it was replaced by AUC0-8 on Day 5; the converse was also true.

Time frame:
ASTX727: Pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8 hours post-dose on Days 1 to 5 of Cycle 1 and 2; Decitabine: Pre-dose, 0.25, 0.5, 1, 1.08, 1.5, 2, 3, 4, 6, 8 hours post-dose on Days 1 to 5 of Cycle 1 and 2 (each cycle= 28 days)
Reported as:
Geometric mean · h*ng/mL
Total 5-day Area Under the Curve From 0 to 8 Hours (AUC0-8) After Treatment With ASTX727 And IV Decitabine
h*ng/mLMDS or CMML: IV DecitabineMDS or CMML: ASTX727AML: IV DecitabineAML: ASTX727
Total 5-day Area Under the Curve From 0 to 8 Hours (AUC0-8) After Treatment With ASTX727 And IV Decitabine856.63 ± 40.6839.37 ± 50.4910.1 ± 52.0883.8 ± 52.1
Statistical analysis
  • MDS or CMML: IV Decitabine vs MDS or CMML: ASTX727 · Ratio of geometric lsm: 97.93 · 90% CI 91.74 to 104.5Analysis was based on ANOVA model with treatment, cycle, and sequence as fixed effects, and participant nested in sequence as a random effect (ratio is Oral/IV).
  • AML: IV Decitabine vs AML: ASTX727 · Ratio of geometric lsm: 97.55 · 90% CI 89.32 to 106.5Analysis was based on ANOVA model with treatment, cycle, and sequence as fixed effects, and participant nested in sequence as a random effect (ratio is Oral/IV).
SecondaryArea Under the Curve From 0 to Infinity (AUC0-inf) After Treatment With ASTX727 And IV Decitabine

AUC0-inf was calculated using the formula AUClast + (Clast / λZ), where Clast is the last quantifiable concentration and λZ is the elimination rate constant. AUC0-inf will be calculated using the linear up-log down method. Summarized data has been reported for cycle 1 and 2.

Time frame:
ASTX727: Pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 24 hours post-dose on Days 1, 2 and 5 of Cycle 1 and 2; Decitabine: Pre-dose, 0.25, 0.5, 1, 1.08, 1.5, 2, 3, 4, 6, 8 hours post-dose on Days 1 and 5 of Cycle 1 and 2 (each cycle= 28 days)
Reported as:
Geometric mean · nanograms*hours per millilitres(ng*h/mL)
Area Under the Curve From 0 to Infinity (AUC0-inf) After Treatment With ASTX727 And IV Decitabine
nanograms*hours per millilitres(ng*h/mL)MDS or CMML: IV DecitabineMDS or CMML: ASTX727AML: IV DecitabineAML: ASTX727
Day 1174 ± 40.8102 ± 54.8175 ± 54.9118 ± 54.4
Day 2—186 ± 55.3—193 ± 59.6
Day 5170 ± 41.7178 ± 52.7181 ± 58.1187 ± 57.1
SecondaryMaximum Observed Plasma Concentration (Cmax) of Decitabine, Cedazuridine, and Cedazuridine-epimer

Summarized data of Cmax on Day 1, 2 and 5 respectively for Cycle 1 and 2 has been reported for ASTX727. Similarly, summarized data of Cmax on Day 1 and 5 respectively for Cycle 1 and 2 has been reported for IV Decitabine.

Time frame:
ASTX727: Pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 24 hours post-dose on Days 1, 2 and 5 of Cycle 1 and 2; Decitabine: Pre-dose, 0.25, 0.5, 1, 1.08, 1.5, 2, 3, 4, 6, 8 hours post-dose on Days 1 and 5 of Cycle 1 and 2 (each cycle= 28 days)
Reported as:
Geometric mean · nanogram per milliliter (ng/mL)
Maximum Observed Plasma Concentration (Cmax) of Decitabine, Cedazuridine, and Cedazuridine-epimer
nanogram per milliliter (ng/mL)MDS or CMML: IV DecitabineMDS or CMML: ASTX727AML: IV DecitabineAML: ASTX727
Decitabine: Day 1184 ± 48.183.1 ± 66.1187 ± 64.785.9 ± 56.6
Decitabine: Day 2—145 ± 54.7—139 ± 58.5
Decitabine: Day 5180 ± 49.2140 ± 62.8192 ± 62.4139 ± 62.7
Cedazuridine: Day 1—321 ± 53.8—313 ± 47.7
Cedazuridine: Day 2—349 ± 49.1—343 ± 43.4
Cedazuridine: Day 5—371 ± 51.8—350 ± 42.7
Cedazuridine-epimer: Day 1—150 ± 65.7—182 ± 60.0
Cedazuridine-epimer: Day 2—155 ± 64.6—204 ± 59.2
Cedazuridine-epimer: Day 5—169 ± 65.9—191 ± 58.4
SecondaryTime to Reach Maximum Plasma Concentration (Tmax) of Decitabine, Cedazuridine, and Cedazuridine-epimer

Summarized data of Tmax on Day 1, 2 and 5 respectively for Cycle 1 and 2 has been reported for ASTX727. Similarly, summarized data of Tmax on Day 1 and 5 respectively for Cycle 1 and 2 has been reported for IV Decitabine.

Time frame:
ASTX727: Pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 24 hours post-dose on Days 1, 2 and 5 of Cycle 1 and 2; Decitabine: Pre-dose, 0.25, 0.5, 1, 1.08, 1.5, 2, 3, 4, 6, 8 hours post-dose on Days 1 and 5 of Cycle 1 and 2 (each cycle= 28 days)
Reported as:
Median · hours
Time to Reach Maximum Plasma Concentration (Tmax) of Decitabine, Cedazuridine, and Cedazuridine-epimer
hoursMDS or CMML: IV DecitabineMDS or CMML: ASTX727AML: IV DecitabineAML: ASTX727
Decitabine: Day 10.98 (0.23 to 1.27)1.00 (0.48 to 3.00)0.98 (0.25 to 2.00)1.00 (0.25 to 2.02)
Decitabine: Day 2—1.00 (0.47 to 2.00)—1.00 (0.25 to 3.00)
Decitabine: Day 50.97 (0.25 to 1.62)1.00 (0.25 to 3.00)0.98 (0.00 to 1.17)1.00 (0.47 to 3.00)
Cedazuridine: Day 1—3.00 (1.50 to 7.97)—3.98 (1.47 to 8.00)
Cedazuridine: Day 2—3.01 (0.52 to 7.88)—4.00 (1.00 to 7.88)
Cedazuridine: Day 5—3.00 (1.50 to 6.12)—3.98 (1.00 to 8.00)
Cedazuridine-epimer: Day 1—3.08 (1.50 to 7.97)—4.00 (1.50 to 8.03)
Cedazuridine-epimer: Day 2—3.03 (0.52 to 7.88)—4.00 (1.50 to 7.88)
Cedazuridine-epimer: Day 5—3.08 (1.00 to 8.05)—4.00 (1.53 to 8.00)
SecondaryApparent Oral Clearance (CL/F) of Oral Decitabine and Cedazuridine

Oral CL/F for oral decitabine was measured only on Day 1 and oral CL/F for oral cedazuridine was measured on Days 1, 2 and 5. Summarized data of Oral CL/F for oral decitabine on Day 1 for Cycle 1 and 2 has been reported for ASTX727. Similarly, summarized data of oral CL/F for oral cedazuridine on Day 1,2 and 5 respectively for Cycle 1 and 2 has been reported for ASTX727.

Time frame:
Pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 24 hours post-dose on Days 1, 2 and 5 of Cycle 1 and 2 (each cycle= 28 days)
Reported as:
Geometric mean · Litres per hour (L/h)
Apparent Oral Clearance (CL/F) of Oral Decitabine and Cedazuridine
Litres per hour (L/h)MDS or CMML: ASTX727AML: ASTX727
Decitabine: Day 1342 ± 54.8297 ± 54.4
Cedazuridine: Day 130.6 ± 46.428.6 ± 55.5
Cedazuridine: Day 225.6 ± 15927.4 ± 45.4
Cedazuridine: Day 516.8 ± 15.986.8 ± NA
SecondaryApparent Elimination Half Life (t1/2) of Decitabine, Cedazuridine, and Cedazuridine-epimer

Summarized data of t1/2 on Day 1, 2 and 5 respectively for Cycle 1 and 2 has been reported for ASTX727. Similarly, summarized data of t1/2 on Day 1 and 5 respectively for Cycle 1 and 2 has been reported for IV Decitabine.

Time frame:
ASTX727: Pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 24 hours post-dose on Days 1, 2 and 5 of Cycle 1 and 2; Decitabine: Pre-dose, 0.25, 0.5, 1, 1.08, 1.5, 2, 3, 4, 6, 8 hours post-dose on Days 1 and 5 of Cycle 1 and 2 (each cycle= 28 days)
Reported as:
Geometric mean · hours
Apparent Elimination Half Life (t1/2) of Decitabine, Cedazuridine, and Cedazuridine-epimer
hoursMDS or CMML: IV DecitabineMDS or CMML: ASTX727AML: IV DecitabineAML: ASTX727
Decitabine: Day 10.967 ± 46.81.18 ± 22.81.16 ± 56.71.07 ± 31.6
Decitabine: Day 2—1.38 ± 24.7—1.36 ± 35.0
Decitabine: Day 51.14 ± 44.91.47 ± 26.91.18 ± 49.01.45 ± 34.0
Cedazuridine: Day 1—6.33 ± 18.1—6.68 ± 18.5
Cedazuridine: Day 2—6.70 ± 18.9—7.05 ± 17.6
Cedazuridine: Day 5—2.59 ± 5.43—2.41 ± NA
Cedazuridine-epimer: Day 1—5.50 ± 21.8—6.22 ± 17.4
Cedazuridine-epimer: Day 2—5.90 ± 23.2—6.15 ± 22.8
Cedazuridine-epimer: Day 5—2.58 ± 5.16—2.57 ± NA
SecondaryApparent Volume of Distribution (Vz/F) of Oral Decitabine and Cedazuridine

Summarized data of Vz/F on Day 1, 2 and 5 respectively for Cycle 1 and 2 has been reported for ASTX727.

Time frame:
Pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 24 hours post-dose on Days 1, 2 and 5 of Cycle 1 and 2 (each cycle= 28 days)
Reported as:
Geometric mean · Litres
Apparent Volume of Distribution (Vz/F) of Oral Decitabine and Cedazuridine
LitresMDS or CMML: ASTX727AML: ASTX727
Decitabine: Day 1585 ± 55.0434 ± 60.4
Decitabine: Day 2369 ± 59.0337 ± 67.6
Decitabine: Day 5417 ± 54.3373 ± 68.9
Cedazuridine: Day 1280 ± 50.9272 ± 59.9
Cedazuridine: Day 2296 ± 51.3278 ± 49.8
Cedazuridine: Day 562.8 ± 10.4302 ± NA
SecondaryMDS/CMML: Percentage of Participants With Complete Response (CR), Marrow CR (mCR), Partial Response (PR), Hematologic Improvement (HI) Based on International Working Group (IWG) 2006 Myelodysplastic Syndromes (MDS) Response Criteria

CR: normal peripheral, persistent granulocyte count ≥1.0x10\^9/liter(L), platelet ≥100x10\^9/L, Hemoglobin (Hgb) ≥11g/dL, normal bone marrow with persistent marrow blasts ≤5%. mCR: reduction of bone marrow blasts to≤5%, decrease by 50% or more with/without normalization of peripheral counts.PR: normal peripheral counts, granulocyte count ≥1.0x10\^9/L, platelet count ≥100x10\^9/L, Hgb ≥11 g/dL, normal bone marrow, marrow blasts \>5%, reduced by 50% or more for at least 4 weeks. HI: HI-E: Hb increase ≥1.5 g/dL in absence of RBC transfusions. HI-P: Absolute increase of platelet count from \<20 to \>20X10\^9/L by at least 100%,if more than 20x10\^9/L, by absolute increase of at least 30x10\^9/L in absence of platelet transfusions. HI-N: granulocyte increase ≥100%, by an absolute increase ≥0.5x10\^9/L for at least 8 weeks. Percentage of participants with CR, mCR, PR, and HI based on IWG 2003 MDS response criteria are reported. Response has been reported based on participants with MDS or CMML.

Time frame:
Up to approximately 2.7 years
Reported as:
Number · percentage of participants
MDS/CMML: Percentage of Participants With Complete Response (CR), Marrow CR (mCR), Partial Response (PR), Hematologic Improvement (HI) Based on International Working Group (IWG) 2006 Myelodysplastic Syndromes (MDS) Response Criteria
percentage of participantsMDS: Sequence A: First ASTX727, Then IV Decitabine, Then ASTX727MDS: Sequence B: First IV Decitabine, Then ASTX727, Then ASTX727CMML: Sequence A: First ASTX727, Then IV Decitabine, Then ASTX727CMML: Sequence B: First IV Decitabine, Then ASTX727, Then ASTX727
Complete Response (CR)26.2 (15.8 to 39.1)19.6 (10.2 to 32.4)0 (0 to 0)18.2 (2.3 to 51.8)
Marrow Complete Response (mCR)29.5 (18.5 to 42.6)30.4 (18.8 to 44.1)40.0 (5.3 to 85.3)54.5 (23.4 to 83.3)
Partial Response (PR)0 (0 to 0)0 (0 to 0)0 (0 to 0)0 (0 to 0)
HI: Erythroid Response (HI-E)0 (0 to 0)1.8 (0.0 to 9.6)20.0 (0.5 to 71.6)0 (0 to 0)
HI: Platelet Response (HI-P)3.3 (0.4 to 11.3)8.9 (3.0 to 19.6)0 (0 to 0)0 (0 to 0)
HI: Neutrophil Response (HI-N)0 (0 to 0)0 (0 to 0)0 (0 to 0)9.1 (0.2 to 41.3)
SecondaryAML: Percentage of Participants With CR, CR With Incomplete Blood Count Recovery (CRi), CR With Incomplete Platelet Recovery (CRp), and CR Plus CRp Based on IWG 2003 AML Response Criteria

CR was defined as absolute neutrophil content (ANC) ≥1000/ microliter (μL), platelets ≥100,000/μL, independence from red blood cell (RBC) and platelet transfusions over the past week, no leukemic blasts and \<5% leukemic blasts. CRp was defined as CR criteria except platelets \<100,000/μL.and platelet transfusion over the past week. CRi was defined as CR criteria except ANC \<1000/μL or platelets \<100,000/μL. Percentage of participants with CR, CRi, CRp, and CR Plus CRp based on IWG 2003 AML response criteria are reported.

Time frame:
Up to approximately 2.4 years
Reported as:
Number · percentage of participants
AML: Percentage of Participants With CR, CR With Incomplete Blood Count Recovery (CRi), CR With Incomplete Platelet Recovery (CRp), and CR Plus CRp Based on IWG 2003 AML Response Criteria
percentage of participantsAML: Sequence A: First ASTX727, Then IV Decitabine, Then ASTX727AML: Sequence B: First IV Decitabine, Then ASTX727, Then ASTX727
Complete Response (CR)14.0 (5.3 to 27.9)29.5 (16.8 to 45.2)
CR with Incomplete Platelet Recovery (CRp)4.7 (0.6 to 15.8)0 (0.0 to 8.0)
CR with Incomplete Blood Count Recovery (CRi)11.6 (3.9 to 25.1)0 (0.0 to 8.0)
CR Plus CRp18.6 (8.4 to 33.4)29.5 (16.8 to 45.2)
SecondaryAML: Percentage of Participants With CR With Partial Hematologic Recovery (CRh) Based on IWG 2003 AML Response Criteria

CRh was defined as \<5% of blasts in the bone marrow, no evidence of disease, and partial recovery of peripheral blood counts (platelets \>50,000/μL and ANC \>500/μL), independence from RBC and platelet transfusions within 7 days of bone marrow evaluation, and peripheral blast ≤1%. Percentage of participants with CRh based on IWG 2003 AML response criteria are reported.

Time frame:
Day 1 of Cycle 3 up to approximately 2.4 years (each cycle= 28 days)
Reported as:
Number · percentage of participants
AML: Percentage of Participants With CR With Partial Hematologic Recovery (CRh) Based on IWG 2003 AML Response Criteria
percentage of participantsAML: Sequence A: First ASTX727, Then IV Decitabine, Then ASTX727AML: Sequence B: First IV Decitabine, Then ASTX727, Then ASTX727
AML: Percentage of Participants With CR With Partial Hematologic Recovery (CRh) Based on IWG 2003 AML Response Criteria4.7 (0.6 to 15.8)0 (0.0 to 8.0)
SecondaryAML: Time to First Response, Best Response and Complete Response Based on IWG 2003 AML Response Criteria

Time to first response was defined as time in months from the date of first treatment to the first date when any response is achieved. Time to best response was defined in months from the date of first treatment to the first date when a subject's best response, in the order of CR, CRi (or CRp or CRh), or PR, was achieved. Time to CR was defined in months from the date of first treatment to the first date when CR is achieved. CR:ANC ≥1000/ microliter (μL),platelets ≥100,000/μL,independence from RBC and platelet transfusions over the past week, no leukemic blasts, and \<5% leukemic blasts.CRp: CR criteria except ANC ≥1000/μL, platelets \< 100,000/μL.and platelet transfusion over the past week. CRi:CR criteria except ANC \<1000/μL or platelets \<100,000/μL.CRh: \<5% of blasts in the bone marrow,platelets \>50,000/μL and ANC \>500/μL, independence from RBC and platelet transfusions within 7 days and peripheral blast ≤1%. PR: CR criteria except decrease of ≥50% in leukemic blasts.

Time frame:
Up to approximately 2.4 years
Reported as:
Median · months
AML: Time to First Response, Best Response and Complete Response Based on IWG 2003 AML Response Criteria
monthsAML: ASTX727 or IV Decitabine
Time to First Response2.91 (1.9 to 6.5)
Time to Best Response3.45 (1.9 to 7.5)
Time to Complete Response3.02 (1.9 to 7.5)
SecondaryAML: Duration of Complete Response and Combined CR and CRh Based on IWG 2003 AML Response Criteria

Duration of CR was defined as the time interval from the first CR to time of relapse. Duration of combined CR and CRh was defined as the time interval from the first CR or CRh to time of relapse. Duration of CR and combined CR and CRh was presented using a Kaplan-Meier estimate.

Time frame:
Up to approximately 2.4 years
Reported as:
Median · months
AML: Duration of Complete Response and Combined CR and CRh Based on IWG 2003 AML Response Criteria
monthsAML: ASTX727 or IV Decitabine
Duration of Complete Response6.9 (3.4 to 11.5)
Duration of Combined CR and CRh9.0 (3.4 to 11.5)
SecondaryMDS/CMML: Percentage of Participants With Red Blood Cell (RBC) and Platelet Transfusion Independence (TI)

Transfusion independence was defined as no transfusion for 56 consecutive days or more (84 and 112 days) after the first dose of study treatment while maintaining hemoglobin ≥8 grams/deciliter (g/dL) (RBC TI) or maintaining platelets ≥20×109/L (platelet TI).

Time frame:
Up to approximately 2.7 years
Reported as:
Number · percentage of participants
MDS/CMML: Percentage of Participants With Red Blood Cell (RBC) and Platelet Transfusion Independence (TI)
percentage of participantsMDS or CMML: ASTX727 or IV Decitabine
RBC TI: ≥56 Days51.9 (37.8 to 65.7)
RBC TI: ≥84 Days40.7 (27.6 to 55.0)
RBC TI: ≥112 Days33.3 (21.1 to 47.5)
Platelet TI: ≥56 Days50.0 (21.1 to 78.9)
Platelet TI: ≥84 Days33.3 (9.9 to 65.1)
Platelet TI: ≥112 Days33.3 (9.9 to 65.1)
SecondaryAML: Percentage of Participants With Red Blood Cell (RBC) and Platelet Transfusion Independence (TI)

Transfusion independence was defined as no transfusion for 56 consecutive days or more (112 days) after the first dose of study treatment while maintaining hemoglobin ≥8 grams/deciliter (g/dL) (RBC TI) or maintaining platelets ≥20×109/L (platelet TI).

Time frame:
Up to approximately 2.4 years
Reported as:
Number · percentage of participants
AML: Percentage of Participants With Red Blood Cell (RBC) and Platelet Transfusion Independence (TI)
percentage of participantsAML: ASTX727 or IV Decitabine
RBC TI ≥56 Days37.8 (22.5 to 55.2)
RBC TI ≥112 Days24.3 (11.8 to 41.2)
Platelet TI ≥56 Days35.7 (12.8 to 64.9)
Platelet TI ≥112 Days28.6 (8.4 to 58.1)
SecondaryMDS/CMML: Leukemia-free Survival (LFS)

LFS was defined as time from the date of randomization to the date when bone marrow or peripheral blood blasts reach ≥20%, or death from any cause. Participants who hadn't reached AML at the time of the analysis were censored at the date of the last follow-up. Leukemia-free survival was presented using a Kaplan-Meier estimate.

Time frame:
From randomization up to approximately 2.7 years
Reported as:
Median · days
MDS/CMML: Leukemia-free Survival (LFS)
daysMDS or CMML: ASTX727 or IV Decitabine
MDS/CMML: Leukemia-free Survival (LFS)889.0 (674.0 to NA)
SecondaryMDS/CMML: Overall Survival (OS)

OS was defined as time from the date of randomization to the date of death from any cause. Participants without documented death at the time of the analysis were censored at the date of the last follow-up. Overall survival was presented using a Kaplan-Meier estimate.

Time frame:
From randomization up to approximately 2.7 years
Reported as:
Median · days
MDS/CMML: Overall Survival (OS)
daysMDS or CMML: ASTX727 or IV Decitabine
MDS/CMML: Overall Survival (OS)966.0 (809.0 to NA)
SecondaryAML: Overall Survival (OS)

OS was defined as time from the date of randomization to the date of death from any cause. Participants without documented death at the time of the analysis were censored at the date of the last follow-up. Overall survival was presented using a Kaplan-Meier estimate.

Time frame:
From randomization up to approximately 2.4 years
Reported as:
Median · months
AML: Overall Survival (OS)
monthsAML: ASTX727 or IV Decitabine
AML: Overall Survival (OS)8.9 (5.9 to 13.1)
SecondaryAML: Survival Rates at 6 Months, 1 Year, and 2 Years

One-year survival rate was defined as the survival rate at the end of the first year from the date of randomization. The survival rates at 6 months and at 2 years were calculated similarly.

Time frame:
At Month 6, Year 1 and 2
Reported as:
Number · percentage of participants
AML: Survival Rates at 6 Months, 1 Year, and 2 Years
percentage of participantsAML: ASTX727 or IV Decitabine
Month 661 (50 to 71)
Year 144 (33 to 54)
Year 216 (8 to 26)
SecondaryAML: Event-free Survival (EFS)

EFS was defined as time from the date of randomization to the date of treatment failure \[disease progression/relapse (due to confirmed reappearance of leukemic blasts in peripheral blood or ≥5% leukemic blasts in bone marrow (including relapse), discontinue treatment due to disease progression or treatment-related AE, or alternative anti-leukemia therapy except for HCT\] or death from any cause, whichever occurs first. Participants without documented treatment failure at the time of the analysis were censored at the date of the last follow-up. Event-free survival was presented using a Kaplan-Meier estimate.

Time frame:
From randomization up to approximately 2.4 years
Reported as:
Median · months
AML: Event-free Survival (EFS)
monthsAML: ASTX727 or IV Decitabine
AML: Event-free Survival (EFS)5.9 (3.8 to 8.5)
SecondaryAML: Progression-free Survival (PFS)

PFS was defined as time from the date of randomization to the date disease progression due to confirmed reappearance of leukemic blasts in peripheral blood or ≥5% leukemic blasts in bone marrow (including relapse) or death from any cause, whichever occurs first. Participants without documented disease progression/relapse or death at the time of the analysis were censored at the date of the last follow-up. Progression-free survival was presented using a Kaplan-Meier estimate.

Time frame:
From randomization up to approximately 2.4 years
Reported as:
Median · months
AML: Progression-free Survival (PFS)
monthsAML: ASTX727 or IV Decitabine
AML: Progression-free Survival (PFS)6.1 (4.0 to 8.7)

Adverse events

Collected over MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
MDS or CMML: IV Decitabine2/132 (1.5%)24/132 (18.2%)127/132 (96.2%)
MDS or CMML: ASTX72756/130 (43.1%)81/130 (62.3%)130/130 (100%)
MDS or CMML: Not Treated0/5 (0%)0/5 (0%)0/5 (0%)
AML: IV Decitabine5/78 (6.4%)19/78 (24.4%)70/78 (89.7%)
AML: ASTX72761/80 (76.3%)65/80 (81.3%)76/80 (95%)
AML: Not Treated2/2 (100%)1/2 (50%)0/2 (0%)
Most frequent serious events
Showing 10 of 147
Most frequent serious events
EventMDS or CMML: IV DecitabineMDS or CMML: ASTX727MDS or CMML: Not TreatedAML: IV DecitabineAML: ASTX727AML: Not Treated
Sudden DeathGeneral disorders0/1320/1300/50/781/801/2
Febrile neutropeniaBlood and lymphatic system disorders8/13233/1300/54/7821/800/2
PneumoniaInfections and infestations6/13217/1300/54/7816/800/2
SepsisInfections and infestations0/13210/1300/50/783/800/2
InfectionInfections and infestations0/1320/1300/51/785/800/2
AnaemiaBlood and lymphatic system disorders0/1322/1300/50/784/800/2
CellulitisInfections and infestations2/1325/1300/51/784/800/2
AstheniaGeneral disorders1/1322/1300/50/783/800/2
Urinary tract infectionInfections and infestations0/1321/1300/50/783/800/2
BronchitisInfections and infestations0/1320/1300/50/783/800/2
Most frequent other events
Showing 10 of 88
Most frequent other events
EventMDS or CMML: IV DecitabineMDS or CMML: ASTX727MDS or CMML: Not TreatedAML: IV DecitabineAML: ASTX727AML: Not Treated
ThrombocytopeniaBlood and lymphatic system disorders52/13290/1300/530/7847/800/2
NeutropeniaBlood and lymphatic system disorders45/13279/1300/58/7827/800/2
AnaemiaBlood and lymphatic system disorders47/13272/1300/521/7841/800/2
FatigueGeneral disorders23/13268/1300/52/789/800/2
ConstipationGastrointestinal disorders26/13264/1300/58/7815/800/2
NauseaGastrointestinal disorders23/13263/1300/54/7817/800/2
DiarrhoeaGastrointestinal disorders14/13254/1300/51/7817/800/2
HeadacheNervous system disorders19/13250/1300/52/786/800/2
DyspnoeaRespiratory, thoracic and mediastinal disorders12/13245/1300/53/784/800/2
Decreased AppetiteMetabolism and nutrition disorders7/13243/1300/55/7812/800/2

Baseline characteristics

The Safety Analysis Set included all participants who received any amount of study treatment.

Age, Customized
Age, Customized(Participants)MDS or CMML: ASTX727 or IV DecitabineAML: ASTX727 or IV DecitabineTotal
18 to 64 years36339
65 to 84 years9375168
≥85 years4913
Sex: Female, Male
Sex: Female, Male(Participants)MDS or CMML: ASTX727 or IV DecitabineAML: ASTX727 or IV DecitabineTotal
Female463480
Male8753140
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)MDS or CMML: ASTX727 or IV DecitabineAML: ASTX727 or IV DecitabineTotal
Hispanic or Latino606
Not Hispanic or Latino1250125
Unknown or Not Reported28789
Race (NIH/OMB)
Race (NIH/OMB)(Participants)MDS or CMML: ASTX727 or IV DecitabineAML: ASTX727 or IV DecitabineTotal
American Indian or Alaska Native000
Asian303
Native Hawaiian or Other Pacific Islander000
Black or African American404
White1210121
More than one race000
Unknown or Not Reported58792
08

Study locations

84 sites
  • Pinnacle Research Group
    Anniston, Alabama 36207, United States
  • Mayo Clinic Arizona
    Phoenix, Arizona 85054, United States
  • Arizona Clinical Research Center
    Tucson, Arizona 85715, United States
  • Compassionate Cancer Care Research Group
    Fountain Valley, California 92708, United States
  • University of Southern California
    Los Angeles, California 90007, United States
  • Yale
    New Haven, Connecticut 06510, United States
  • Georgetown University
    Washington, District of Columbia 20007, United States
  • Boca Raton Clinical Research
    Boca Raton, Florida 33322, United States
  • Holy Cross Hospital
    Fort Lauderdale, Florida 33308, United States
  • Mount Sinai
    Miami Beach, Florida 33140, United States
  • Rush University Medical Center
    Chicago, Illinois 60612, United States
  • University of Chicago
    Chicago, Illinois 60637, United States
  • Quincy Medical Group
    Quincy, Illinois 62301, United States
  • Indiana Blood and Marrow Transplantation
    Indianapolis, Indiana 46237, United States
  • Norton Cancer Institute
    Louisville, Kentucky 40207, United States
  • Johns Hopkins
    Baltimore, Maryland 21287, United States
  • Regional Cancer Care Associates
    Bethesda, Maryland 20817, United States
  • Michigan Center of Medical Research
    Farmington Hills, Michigan 48334, United States
  • Cancer & Hematology Centers of Western Michigan
    Grand Rapids, Michigan 49503, United States
  • Mayo Clinic Rochester
    Rochester, Minnesota 55905, United States
  • Hackensack
    Hackensack, New Jersey 07601, United States
  • Montefiore
    Bronx, New York 10467, United States
  • Roswell Park
    Buffalo, New York 14263, United States
  • Monter Cancer Center
    Lake Success, New York 11042, United States
  • Weill Cornell Medicine
    New York, New York 10065, United States
  • Gabrail Cancer Center
    Canton, Ohio 44718, United States
  • Ohio State University
    Columbus, Ohio 43210, United States
  • Oregon Health & Sciences University
    Portland, Oregon 20817, United States
  • West Penn Allegheny Cancer Institute
    Pittsburgh, Pennsylvania 15224, United States
  • University of Pittsburgh Hillman Cancer Center
    Pittsburgh, Pennsylvania 15232, United States
  • Charleston Hematology Oncology Associates
    Charleston, South Carolina 29414, United States
  • Vanderbilt
    Nashville, Tennessee 37232, United States
  • Baylor Scott & White University Medical Center
    Dallas, Texas 75246, United States
  • University of Texas Southwestern Medical Center
    Dallas, Texas 75390-9179, United States
  • Houston Methodist Cancer Center
    Houston, Texas 77030, United States
  • MD Anderson Cancer Center
    Houston, Texas 77030, United States
  • Utah Cancer Specialists
    Salt Lake City, Utah 84124, United States
  • Kadlec Clinic Hematology and Oncology
    Kennewick, Washington 99336, United States
  • Fred Hutchinson Cancer Research Center
    Seattle, Washington 98109, United States
  • Uniklinikum Salzburg
    Salzburg, 05020, Austria
  • General Hospital Hietzing
    Vienna, 01130, Austria
  • Klinikum Wels-Grieskirchen
    Wels, 4600, Austria
  • University of Alberta Hospital
    Edmonton, Alberta T6G 2B7, Canada
  • Queen Elizabeth II (QEII) Health Sciences Center
    Halifax, Nova Scotia B3H 2Y9, Canada
  • Juravinski Hospital & Cancer Center
    Hamilton, Ontario L8V 1C3, Canada
  • Ottawa Hospital - General Campus
    Ottawa, Ontario K1H8L6, Canada
  • Sunnybrook Health Sciences Centre
    Toronto, Ontario M4N 3M5, Canada
  • Princess Margaret Cancer Center - University Health Network
    Toronto, Ontario M5G 2M9, Canada
  • Centre Intégré Universitaire de Santé et de Services Sociaux (CIUSSS) de l'Est-de-l'Ile-de-Montréal - Hôpital Maisonneuve Rosemont
    Montréal, Quebec H1T 2M4, Canada
  • FN Ostrava
    Ostrava, Poruba 708 00, Czechia
  • University Hospital Brno
    Brno, 62500, Czechia
  • Fakultni Nemocnice Kralovske Vinohrady FNKV
    Praha 10, Česká Republika 10034, Czechia
  • Centre de lutte contre le Cancer Leon Berard
    Lyon, Rhone 69008, France
  • Hospital Emile Muller
    Mulhouse, 68100, France
  • Universitaetsklinikum Freiburg
    Freiburg im Breisgau, Baden 79106, Germany
  • Philipps-Universität Marburg, Klinik für Innere medizin, Hämatologie, Onkologie und Immunologie
    Marburg, Hesse 35033, Germany
  • UNIVERSITTSKLINIKUM Schleswig-Holstein
    Lubeck, Schleswig-Holstein 23538, Germany
  • Staedtisches Klinikum Braunschweig
    Braunschweig, 38114, Germany
  • Oberärztin für Innere Medizin, Hämato-/Onkologie und Palliativmedizin
    Düsseldorf, 40479, Germany
  • University Hospital Halle
    Halle, 06120, Germany
  • University of Leipzig
    Leisnig, 04103, Germany
  • Debreceni Egyetem Klinikai Kozpont
    Debrecen, 4032, Hungary
  • Somogy Megyei KAposi Mor Oktato Korhaz
    Kaposvár, 7400, Hungary
  • University of Pecs, 1st Department of Internal Medicine
    Pecs, 7400, Hungary
  • University of Szeged
    Szeged, 6725, Hungary
  • Azienda Ospedaliera Nazionale SS. Antonio e Biagio e C. Arrigo
    Alessandria, 15121, Italy
  • AOUC Azienda Ospedaliero-Universitaria Careggi
    Firenze, 50134, Italy
  • Fondazione IRCCS C Granda OM Policlinico
    Milan, 20122, Italy
  • Azienda Ospedaliero-Universitaria Maggiore della Carità Novara
    Novara, 28100, Italy
  • Ospedale S. Eugenio
    Rome, 00144, Italy
  • ULSS 8 Vicenza - Ospedale San Bortolo di Vicenza
    Vicenza, 36100, Italy
  • Hospital Universitario Central de Asturias
    Oviedo, Asturias 33011, Spain
  • Hospital U. Marqués de Valdecilla
    Santander, Cantabria 39008, Spain
  • Hospital San Pedro de Alcantara
    Cáceres, 10003, Spain
  • Hospital Universitario Virgen de las Nieves
    Granada, 18012, Spain
  • Hospital Duran i Reynals
    L'Hospitalet De Llobregat, 08909, Spain
  • Hospital General Universitario Gregorio Marañón
    Madrid, 28007, Spain
  • Clinica Universitaria Navarra
    Madrid, 28027, Spain
  • Hospital Universitario 12 de Octubre
    Madrid, 28041, Spain
  • Clinica Universitaria Navarra
    Pamplona, 31008, Spain
  • Hospital Universitario de Salamanca
    Salamanca, 37007, Spain
  • Hospital Universitari I Politècnic La Fe
    València, 46026, Spain
  • Oxford University Hopsitals NHS Trust
    Oxford, Oxfordshire OX3 7LE, United Kingdom
  • The Christie NHS Fundation Trust
    Manchester, M20 4BX, United Kingdom
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2018 to primary completion in Sep 2021, 42 months.

Results were first posted in Jul 2024, 2 years 9 months after primary completion. A results delay was requested in Jul 2022.

Of 26 industry-sponsored phase 3 interventional studies under Myelodysplastic Syndromes, half reached primary completion within 42 months of starting (the median), counting those still running; a quarter within 33 and three quarters within 52. This study's 42 months is close to that.

Counting every sponsor, half of 46 studies reached it within 48 months; a quarter within 37 and three quarters within 95.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 2, 2017
First posted
Oct 11, 2017
StartActual
Feb 15, 2018
Primary completionActual
Sep 10, 2021
CompletionActual
May 25, 2023
Results delay requested
Jul 29, 2022
Results first posted
Jul 1, 2024
Last update
Aug 27, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 27, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03306264
Responsible party
Sponsor
First posted
Oct 11, 2017
Start date
Feb 15, 2018
Primary completion
Sep 10, 2021
Completion
May 25, 2023
Results posted
Jul 1, 2024
Last update
Aug 27, 2024

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion